Oncogenic K-ras activates p38 to maintain colorectal cancer cell proliferation during MEK inhibition.

CONCLUSION: Oncogenic K-ras activates p38alpha to maintain cell proliferation during MEK inhibition. MEK-targeting therapeutics can create an acquired tumor cell dependency on p38alpha. PMID: 20413844 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/pubmed/20413844?dopt=Abstract

Source: Analytical Cellular Pathology - November 25, 2014 Category: Cancer & Oncology Tags: Cell Oncol Source Type: research